- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00400764
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
A Phase Ib/II, Open-Label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Dulanermin Administered Intravenously in Combination With Rituximab to Subjects With Follicular and Other Low-Grade, CD20+, B-Cell Non-Hodgkin's Lymphomas That Have Progressed Following Previous Rituximab Therapy
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Signed Informed Consent Form
- Age ≥ 18 years
- History of histologically confirmed CD20+ follicular NHL Grade 1, 2, or 3a
- Progression of disease following the most recent treatment with rituximab-containing therapy that resulted in stable disease or a partial or complete response lasting ≥ 6 months
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- For subjects of reproductive potential (males and females), use of a reliable means of contraception (e.g., contraceptive pill, intrauterine device [IUD], physical barrier throughout the trial and for 1 year following their final exposure to study treatment).
- Life expectancy of > 3 months
Exclusion Criteria:
- Prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure response unless that lesion shows unequivocal progression at baseline
- Radiation therapy to a peripheral lesion within 14 days prior to Day 1; Radiation therapy to a thoracic, abdominal, or pelvic field within 28 days prior to Day 1
- Chemotherapy, hormonal therapy, radiotherapy, or immunotherapy within 4 weeks prior to Day 1
- Patients who have received radioimmunotherapy for relapsed or refractory, follicular NHL are eligible for the study if they received this therapy at least 1 year prior to Day 1, they have adequate bone marrow function, and they have no evidence of myelodysplastic syndrome on bone marrow aspirate/biopsy
- Prior treatment with dulanermin or an agonist antibody to DR4 or DR5
- Concurrent systemic corticosteroid therapy
- Evidence of clinically detectable ascites on Day 1
- Other invasive malignancies within 5 years prior to Day 1
- History or evidence upon physical examination of central nervous system (CNS) disease within 1 year prior to study entry
- Active infection requiring parenteral antibiotics on Day 1
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study and fine needle aspirations within 7 days prior to Day 1
- Pregnancy or lactation
- Serious nonhealing wound, ulcer, or bone fracture
- Current or recent participation in another experimental drug study
- Clinically significant cardiovascular disease
- Known positive test result for HIV, hepatitis B surface antigen (sAg), hepatitis B IgG or IgM core antibody, or hepatitis C antibody
- Known sensitivity to murine or human antibodies
- History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Phase Ib: Dulanermin 4 mg/kg
Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
|
Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
|
Eksperimentel: Phase Ib: Dulanermin 8 mg/kg
Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
|
Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
|
Aktiv komparator: Phase II: Rituximab
Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
|
Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
|
Eksperimentel: Phase II: Combination Therapy
Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
|
Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
|
Eksperimentel: Phase II: Dulanermin
Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
|
Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Phase Ib: Number of Participants With a Dose-limiting Toxicity
Tidsramme: The DLT assessment window was defined as the duration required to complete two full cycles of treatment with dulanermin (2 * 21 days) and four doses of rituximab (usually through Day 28).
|
A dose-limiting toxicity (DLT) was defined as a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 Grade ≥ 3 hematologic or major organ toxicity that was related to study drug (i.e., dulanermin).
Although a patient may have experienced a DLT at any time during the study, only events that occurred within the DLT assessment window were considered for dose-escalation decisions and determination of the maximum tolerated dose (MTD).
|
The DLT assessment window was defined as the duration required to complete two full cycles of treatment with dulanermin (2 * 21 days) and four doses of rituximab (usually through Day 28).
|
Number of Participants With Treatment-Emergent Adverse Events by Severity Grade
Tidsramme: From Baseline through Study Termination (up to a maximum of approximately 13 months for phase Ib and up to approximately 33 months for phase II)
|
Safety was assessed through summaries of treatment-emergent adverse events (AEs); AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0, according to the following guidelines: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (Life-threatening or disabling) and Grade 5 (Death related to AE).
|
From Baseline through Study Termination (up to a maximum of approximately 13 months for phase Ib and up to approximately 33 months for phase II)
|
Phase II: Objective Response as Assessed by the Independent Review Facility (IRF)
Tidsramme: From Baseline through Study Termination (up to approximately 33 months)
|
Objective response was defined as a confirmed or unconfirmed complete response (CR, CRu) or partial response (PR) assessed on the basis of clinical, radiographic (computed tomography (CT) scans of the neck, chest, abdomen, pelvis and inguinal region), and pathologic (i.e., bone marrow) criteria and according to the modified International Working Group (IWG) criteria. All radiographic and clinical data for the evaluation of objective response were submitted to an IRF for blinded and impartial assessment. Patients without a post-baseline tumor assessment were considered non-responders. |
From Baseline through Study Termination (up to approximately 33 months)
|
Vital Signs: Change From Baseline in Diastolic and Systolic Blood Pressure at Treatment Termination Visit
Tidsramme: Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms)
|
Blood pressure was measured at baseline and throughout the study.
Change from baseline was calculated using the patient's last recorded measurement at the completion of treatment visit - baseline measurement.
|
Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms)
|
Vital Signs: Change From Baseline in Heart Rate at Treatment Termination Visit
Tidsramme: Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms)
|
Heart rate was measured at baseline and throughout the study.
Change from baseline was calculated using the patient's last recorded measurement at the completion of treatment visit - baseline measurement.
|
Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms)
|
Vital Signs: Change From Baseline in Body Temperature at Treatment Termination Visit
Tidsramme: Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms)
|
Body temperature was measured at baseline and throughout the study.
Change from baseline was calculated using the patients last recorded measurement at the completion of treatment visit - baseline measurement.
|
Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms)
|
Number of Participants With a Clinically Significant Laboratory Abnormality
Tidsramme: Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms).
|
Laboratory Parameters were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).
A clinically significant abnormality was defined as a Grade 3 (severe) or Grade 4 (very severe, life threatening, or disabling) laboratory toxicity according to the NCI CTCAE v3.0.
|
Baseline and Treatment Termination visit (8 weeks for Rituximab arm and 12 weeks for combination and Dulanermin arms).
|
Mean Serum Concentration of Dulanermin
Tidsramme: Blood samples were taken 0.5, 1.5, 2, 3, 5, 7 and 24 hours after the start of the infusion on Day 1 of Cycle 1.
|
The dulanermin serum concentration was measured using enzyme linked immunosorbent assay (ELISA).
|
Blood samples were taken 0.5, 1.5, 2, 3, 5, 7 and 24 hours after the start of the infusion on Day 1 of Cycle 1.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Phase II: Progression Free Survival
Tidsramme: From Baseline through Study Termination (up to approximately 33 months)
|
Progression free survival (PFS) was defined as the time from randomization to documented disease progression or death, whichever occurred first and was based on the investigator's assessment using the modified IWG criteria.
Kaplan-Meier methods were used to estimate median time to PFS.
Data for patients without disease progression or death on study were censored at the time of the last tumor assessment.
|
From Baseline through Study Termination (up to approximately 33 months)
|
Phase II: Overall Survival
Tidsramme: From Baseline through Study Termination (up to approximately 33 months)
|
Median overall survival could not be estimated because of the low number of deaths at the time of study termination.
|
From Baseline through Study Termination (up to approximately 33 months)
|
Phase II: Objective Response as Assessed by the Investigator
Tidsramme: From Baseline through Study Termination (up to approximately 33 months)
|
Objective response was defined as a confirmed or unconfirmed complete response(CR, CRu) or partial response (PR) assessed on the basis of clinical, radiographic (computed tomography (CT) scans of the neck, chest, abdomen, pelvis and inguinal region), and pathologic (i.e., bone marrow) criteria and according to the modified International Working Group (IWG) criteria.
Patients without a post-baseline tumor assessment were considered non-responders.
|
From Baseline through Study Termination (up to approximately 33 months)
|
Phase II: Duration of Response as Assessed by the Investigator
Tidsramme: From Baseline through Study Termination (up to approximately 33 months)
|
An event was defined as documented disease progression or death on study, whichever occurred first. Duration of objective response was defined only for patients with an objective response as determined by the investigator and was the time from the initial response to disease progression or death on study. Kaplan-Meier methods were used to estimate median, percentiles, and range of duration of response. |
From Baseline through Study Termination (up to approximately 33 months)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Chia Portera, PhD., M.D, Genentech, Inc.
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Lymfom
- Lymfom, Non-Hodgkin
- Lægemidlers fysiologiske virkninger
- Antirheumatiske midler
- Antineoplastiske midler
- Immunologiske faktorer
- Antineoplastiske midler, immunologiske
- Rituximab
Andre undersøgelses-id-numre
- APO3585g
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Non-Hodgkins lymfom
-
Marker Therapeutics, Inc.RekrutteringNon Hodgkin lymfom | Non-Hodgkin lymfom, voksen | Non-Hodgkin lymfom, refraktær | Non-Hodgkin lymfom, tilbagefaldForenede Stater
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Ikke rekrutterer endnuLymfom | Lymfom, Non-Hodgkin | Non-Hodgkins lymfom | Non-Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Refraktær non-Hodgkin lymfom | Højgradigt B-celle lymfom | CNS lymfom | Lymfomer Non-Hodgkins B-celle | Recidiverende non-Hodgkin lymfom | Lymfom, Non-Hodgkins | Stort B-celle lymfom | Lymfom, Non-Hodgkins... og andre forhold
-
Caribou Biosciences, Inc.RekrutteringLymfom | Lymfom, Non-Hodgkin | B-celle lymfom | Non Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Recidiverende non-hodgkin lymfom | B-celle non-Hodgkins lymfomForenede Stater, Australien, Israel
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAfsluttetLymfom, Non-Hodgkin | Lymfomer: Non-Hodgkin | Lymfomer: Non-Hodgkin perifer T-celle | Lymfomer: Non-Hodgkin kutan lymfom | Lymfomer: Non-Hodgkin diffuse store B-celler | Lymfomer: Non-Hodgkin follikulært / indolent B-celle | Lymfomer: Non-Hodgkin kappecelle | Lymfomer: Non-Hodgkin Marginal Zone | Lymfomer...Forenede Stater
-
Chongqing Precision Biotech Co., LtdRekrutteringNon Hodgkin lymfom | Refraktær non-Hodgkin lymfom | Recidiverende non-Hodgkin lymfomKina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringRefraktær B-celle non-Hodgkin lymfom | Tilbagevendende B-celle non-Hodgkin lymfom | Højgradig B-celle non-Hodgkins lymfom | Mellemklasse B-celle non-Hodgkins lymfomForenede Stater
-
Memorial Sloan Kettering Cancer CenterRekrutteringNon-Hodgkin lymfom | Non-Hodgkins lymfom, tilbagefald | Non-Hodgkins lymfom refraktærForenede Stater
-
Mayo ClinicIkke rekrutterer endnuIndolent B-celle non-Hodgkin lymfom | Tilbagevendende indolent non-Hodgkin-lymfom | Refraktært indolent non-Hodgkin lymfom | Tilbagevendende indolent B-celle non-Hodgkin lymfom | Refraktært indolent B-celle non-Hodgkin lymfomForenede Stater
-
Caribou Biosciences, Inc.Tilmelding efter invitationLymfom | Lymfom, Non-Hodgkin | B-celle lymfom | Non-Hodgkin lymfom | Refraktær B-celle non-Hodgkin lymfom | Hæmatologisk malignitet | Recidiverende non-Hodgkin lymfom | B-celle non-Hodgkins lymfomForenede Stater
-
The First Affiliated Hospital of Soochow UniversityShanghai Unicar-Therapy Bio-medicine Technology Co.,LtdRekrutteringRefraktær non-Hodgkin lymfom | Recidiverende non-hodgkin lymfomKina
Kliniske forsøg med Dulanermin
-
University of Alabama at BirminghamNational Institutes of Health (NIH); Fogarty International Center of the...Aktiv, ikke rekrutterendeHepatocellulært karcinom | Fibrose, lever | HBV | Cirrhose, lever | Humant immundefektvirus | Alkoholisk hepatitis | Hepatitis Delta VirusZambia
-
Shanghai Gebaide Biotechnology Co., Ltd.UkendtIkke-småcellet lungekræft (NSCLC) Stadium IVKina
-
Genentech, Inc.Afsluttet
-
Genentech, Inc.Afsluttet
-
AmgenGenentech, Inc.Afsluttet